MA37445B1 - Lyophilisation d'agent tensioactif pulmonaire liposomal synthétique - Google Patents

Lyophilisation d'agent tensioactif pulmonaire liposomal synthétique

Info

Publication number
MA37445B1
MA37445B1 MA37445A MA37445A MA37445B1 MA 37445 B1 MA37445 B1 MA 37445B1 MA 37445 A MA37445 A MA 37445A MA 37445 A MA37445 A MA 37445A MA 37445 B1 MA37445 B1 MA 37445B1
Authority
MA
Morocco
Prior art keywords
lyophilization
pulmonary surfactant
synthetic
synthetic liposomal
liposomal pulmonary
Prior art date
Application number
MA37445A
Other languages
English (en)
French (fr)
Other versions
MA37445A1 (fr
Inventor
Sergio Cesco-Cancian
Thomas Hoy
Edward H Trappler
Michael S Thomas
Original Assignee
Discovery Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Lab Inc filed Critical Discovery Lab Inc
Publication of MA37445A1 publication Critical patent/MA37445A1/fr
Publication of MA37445B1 publication Critical patent/MA37445B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0082Lung surfactant, artificial mucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785Alveolar surfactant peptides; Pulmonary surfactant peptides
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MA37445A 2012-03-28 2014-10-22 Lyophilisation d'agent tensioactif pulmonaire liposomal synthétique MA37445B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616827P 2012-03-28 2012-03-28
PCT/US2013/034464 WO2013149074A1 (en) 2012-03-28 2013-03-28 Lyophilization of synthetic liposomal pulmonary surfactant

Publications (2)

Publication Number Publication Date
MA37445A1 MA37445A1 (fr) 2016-04-29
MA37445B1 true MA37445B1 (fr) 2017-01-31

Family

ID=48096305

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37445A MA37445B1 (fr) 2012-03-28 2014-10-22 Lyophilisation d'agent tensioactif pulmonaire liposomal synthétique

Country Status (35)

Country Link
US (3) US9554999B2 (enrdf_load_html_response)
EP (2) EP2723323B1 (enrdf_load_html_response)
JP (1) JP6178402B2 (enrdf_load_html_response)
KR (1) KR102123129B1 (enrdf_load_html_response)
CN (1) CN104271118B (enrdf_load_html_response)
AU (2) AU2013237985B2 (enrdf_load_html_response)
BR (1) BR112014024057A8 (enrdf_load_html_response)
CA (1) CA2867649C (enrdf_load_html_response)
CL (1) CL2014002553A1 (enrdf_load_html_response)
CO (1) CO7081146A2 (enrdf_load_html_response)
CR (1) CR20140449A (enrdf_load_html_response)
CU (1) CU20140116A7 (enrdf_load_html_response)
CY (1) CY1117380T1 (enrdf_load_html_response)
DK (1) DK2723323T3 (enrdf_load_html_response)
EC (1) ECSP14024363A (enrdf_load_html_response)
ES (1) ES2557805T3 (enrdf_load_html_response)
HK (1) HK1206979A1 (enrdf_load_html_response)
HR (1) HRP20151392T1 (enrdf_load_html_response)
HU (1) HUE026363T2 (enrdf_load_html_response)
IL (1) IL234688B (enrdf_load_html_response)
IN (1) IN2014DN08538A (enrdf_load_html_response)
MA (1) MA37445B1 (enrdf_load_html_response)
MX (1) MX359654B (enrdf_load_html_response)
MY (1) MY164868A (enrdf_load_html_response)
NZ (1) NZ630219A (enrdf_load_html_response)
PE (1) PE20142302A1 (enrdf_load_html_response)
PL (1) PL2723323T3 (enrdf_load_html_response)
PT (1) PT2723323E (enrdf_load_html_response)
RS (1) RS54513B1 (enrdf_load_html_response)
RU (1) RU2671500C2 (enrdf_load_html_response)
SG (1) SG11201405944PA (enrdf_load_html_response)
SI (1) SI2723323T1 (enrdf_load_html_response)
SM (1) SMT201500320B (enrdf_load_html_response)
WO (2) WO2013149013A1 (enrdf_load_html_response)
ZA (1) ZA201406982B (enrdf_load_html_response)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014024057A8 (pt) * 2012-03-28 2018-01-16 Discovery Lab Inc processo para fabricar um tensoativo pulmonar sintético liofilizado, composição de tensoativo pulmonar sintético liofilizado, e, tensoativo pulmonar sintético liofilizado
JP6557935B2 (ja) * 2014-11-18 2019-08-14 国立研究開発法人物質・材料研究機構 多孔性粒子の製造方法
KR101801566B1 (ko) * 2014-12-30 2017-11-28 주식회사 삼양바이오팜 고분자 나노입자 동결건조물 및 그 제조방법
ES2866050T3 (es) * 2015-07-10 2021-10-19 Byondis Bv Composiciones que comprenden conjugados de anticuerpos-fármaco duocarmicina
PL3324932T3 (pl) 2015-07-22 2021-07-05 Nitto Denko Corporation Kompozycje i sposoby dla liofiliozwanych postaci nanocząstek
JP7012512B2 (ja) * 2017-11-13 2022-01-28 清水建設株式会社 管理装置、製造システムおよび管理方法
CA3085944A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
CN108853061A (zh) * 2018-10-09 2018-11-23 兆科药业(合肥)有限公司 一种人工合成肺表面活性剂药物组合物及与之的肠溶胶囊和其制备方法及用途
WO2020142420A1 (en) * 2018-12-31 2020-07-09 Novus Therapeutics, Inc. Novel surfactant-lipid alloy drug substance, methods of making the same, and pharmaceutical compositions comprising the same
US11287185B1 (en) 2020-09-09 2022-03-29 Stay Fresh Technology, LLC Freeze drying with constant-pressure and constant-temperature phases
KR102545292B1 (ko) * 2021-01-28 2023-06-16 인천대학교 산학협력단 마이크로캡슐 형성용 생체 적합 계면활성제 합성방법
AR126368A1 (es) * 2021-07-05 2023-10-11 Chiesi Farm Spa Proceso para la preparación de un tensioactivo pulmonar

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751108R (fr) 1969-06-06 1970-11-03 Berliet Automobiles Dispositif pour la mesure precise de la consommation specifiquedes moteurs a combustion
JPS59164724A (ja) * 1983-03-10 1984-09-17 Tokyo Tanabe Co Ltd サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
TR199801408T2 (xx) 1996-01-24 1998-10-21 Byk, Gulden Lomberg Chemische Fabrik Gmbh Toz halinde pulmoner s�rfaktan preparatlar�n �retimi i�in y�ntem.
WO1997035882A1 (en) * 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US7638493B2 (en) 2004-04-29 2009-12-29 Sannamu Lee Artificial pulmonary surfactant compositions and use of the same
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
EP1912667B1 (en) 2005-07-22 2012-08-29 Amgen Inc. Concentrated protein lyophilates, methods, and uses
EP1997502A1 (en) 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
BR112014024057A8 (pt) * 2012-03-28 2018-01-16 Discovery Lab Inc processo para fabricar um tensoativo pulmonar sintético liofilizado, composição de tensoativo pulmonar sintético liofilizado, e, tensoativo pulmonar sintético liofilizado

Also Published As

Publication number Publication date
NZ630219A (en) 2016-09-30
DK2723323T3 (en) 2016-01-11
MX359654B (es) 2018-10-05
CR20140449A (es) 2015-05-04
PT2723323E (pt) 2016-01-27
MA37445A1 (fr) 2016-04-29
AU2017239624A1 (en) 2017-10-26
BR112014024057A2 (enrdf_load_html_response) 2017-06-20
AU2013237985A1 (en) 2014-10-02
SG11201405944PA (en) 2014-10-30
AU2013237985B2 (en) 2017-07-06
WO2013149074A1 (en) 2013-10-03
KR20140137453A (ko) 2014-12-02
PE20142302A1 (es) 2015-01-21
CO7081146A2 (es) 2014-10-10
CU20140116A7 (es) 2015-01-29
IL234688A0 (en) 2014-11-30
HK1206979A1 (en) 2016-01-22
CL2014002553A1 (es) 2015-04-06
JP2015514714A (ja) 2015-05-21
HUE026363T2 (en) 2016-06-28
CY1117380T1 (el) 2017-04-26
US20140088026A1 (en) 2014-03-27
MY164868A (en) 2018-01-30
RU2014143247A (ru) 2016-05-20
EP2723323B1 (en) 2015-09-23
ECSP14024363A (es) 2015-09-30
CA2867649C (en) 2021-02-16
CN104271118A (zh) 2015-01-07
PL2723323T3 (pl) 2016-05-31
EP2837377A1 (en) 2015-02-18
SI2723323T1 (sl) 2016-04-29
MX2014011483A (es) 2014-12-08
US9554999B2 (en) 2017-01-31
US20150297524A1 (en) 2015-10-22
IL234688B (en) 2020-01-30
US20140088025A1 (en) 2014-03-27
KR102123129B1 (ko) 2020-06-15
HRP20151392T1 (hr) 2016-03-25
CN104271118B (zh) 2017-02-08
WO2013149013A1 (en) 2013-10-03
RU2671500C2 (ru) 2018-11-01
IN2014DN08538A (enrdf_load_html_response) 2015-05-15
HK1197174A1 (zh) 2015-01-09
JP6178402B2 (ja) 2017-08-09
ZA201406982B (en) 2016-05-25
EP2723323A1 (en) 2014-04-30
HK1205685A1 (en) 2015-12-24
AU2017239624B2 (en) 2017-11-23
ES2557805T3 (es) 2016-01-28
CA2867649A1 (en) 2013-10-03
US8748397B2 (en) 2014-06-10
US8748396B2 (en) 2014-06-10
SMT201500320B (it) 2016-02-25
BR112014024057A8 (pt) 2018-01-16
RS54513B1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MA37445B1 (fr) Lyophilisation d'agent tensioactif pulmonaire liposomal synthétique
WO2015010009A3 (en) Compositions and methods comprising a lipolytic enzyme variant
MX394383B (es) Composiciones y metodos que comprenden variante de enzima lipolitica.
BR112012012460A2 (pt) "método de liofilização, composições e kits".
BR112014009305A2 (pt) lipossomas liofilizadas
CL2015000499A1 (es) Uso de un agente farmacéuticamente aceptable que elimina el antígeno de superficie de la hepatitis b de la sangre y un segundo agente que estimula la función inmunitaria, para tratar hepatitis b o coinfección hepatitis b/hepatitis d; y composición que comprende ambos agentes.
ZA200701577B (en) Lyopholization of virosomes
WO2014096440A3 (en) Albumin composition for preventing and/or reducing formation of peptide fibrils
ES2543850R2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
PH12012501562A1 (en) Immunization compositions and methods
HK1207006A1 (en) Daptomycin formulations and uses thereof
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
WO2013111012A3 (en) Methods and compositions for therapeutic agents
CY1119064T1 (el) Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων
EP2747779A4 (en) HERPES SIMPLEX VIRUS VACCINE NANOEMULSION
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
WO2018085551A3 (en) Formulations of pegylated arginine deiminase
EA201300947A1 (ru) Композиция для повышения устойчивости суставов и/или позной устойчивости
CN302267290S (zh) 汽车
CN302267285S (zh) 汽车
TH101482B (th) อนุพันธ์ของสารประกอบ 2,4-ไดอะมิโน-6-เอทธิลไพริมิดีน (2,4-diamino-6-ethylpyrimidine) ที่ออกฤทธิ์ยับยั้งเชื้อพลาสโมเดียมฟาลชิปารัม
CN302065409S (zh) 边梁型钢(1)
CN302082995S (zh) 边梁型钢(2)
TR201001178U (tr) Mobilya süsleme aparatları için "U" formlu dikme parçası.